Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

NCT00665041 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

DRUG: Quinagolide

Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA